Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer.

Cell reports. Medicine - 17 Nov 2020

Brown Wells S, McDonald Paul C, Nemirovsky Oksana, Awrey Shannon, Chafe Shawn C, Schaeffer David F, Li Jinyang, Renouf Daniel J, Stanger Ben Z, Dedhar Shoukat

Abstract excerpt

Activating KRAS mutations are found in over 90% of pancreatic ductal adenocarcinomas (PDACs), yet KRAS has remained a difficult target to inhibit pharmacologically. Here, we demonstrate, using several human and mouse models of PDACs, rapid acquisition of tumor resistance in response to targeting KRAS or MEK, associated with integrin-linked kinase (ILK)-mediated increased phosphorylation of the mTORC2 component...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to MAP Kinase Signaling System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mechanistic Target of Rapamycin Complex 1

Share to Mechanistic Target of Rapamycin Complex 2

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Mitogen-Activated Protein Kinase Kinases

Share to Pancreatic Ducts

Source

Open in PubMed Open full text

Identifiers

PMID: 33294856
DOI: 10.1016/j.xcrm.2020.100131
PMCID: PMC7691443

Genes

KRAS
ILK

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer.PMID 33294856Read ↗

KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.Semantic proximity Read ↗

A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.Semantic proximity Read ↗

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.Semantic proximity Read ↗

Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.Semantic proximity Read ↗

Molecular dissection of pancreatic cancer signaling: Toward targeted therapies for KRAS, MDM2-TP53, EGFR, and PI3K/AKT/mTOR.Semantic proximity Read ↗

Novel therapeutic approaches for pancreatic cancer by combined targeting of RAF→MEK→ERK signaling and autophagy survival responseSemantic proximity Read ↗

Altered PI3K and ERK/MAPK Signaling in KRASG12R-Driven Pancreatic Cancer Presents Opportunities for Precision Therapy.Semantic proximity Read ↗

Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer.Semantic proximity Read ↗

Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancersSemantic proximity Read ↗

A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic CancerSemantic proximity Read ↗

Targeting KRAS mutations in pancreatic cancer: opportunities for future strategiesSemantic proximity Read ↗

Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.